The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease.
The shot, called RTS,S or Mosquirix and developed by British drugmaker GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative, would be the first licensed human vaccine against a parasitic disease and could help prevent millions of cases of malaria in countries that use it.
Mosquirix, also part-funded by the Bill & Melinda Gates Foundation, will now be assessed by the World Health Organization, which has promised to give its guidance on when and where it should be used before the end of this year.
killed an estimated 584,000 people in 2013, the vast majority of them in sub-Saharan Africa
. More than 80 percent of malaria
deaths are in children under the age of five.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>